Imagine the lungs as a fortress that the current TB vaccine can't fully protect. This work figures out exactly how the fortress's guards behave to design a better shield. It's like upgrading a basic lock to a high-tech security system that stops the intruder right at the front door.
The only existing TB vaccine (BCG) fails to prevent pulmonary TB in adults. There is a critical lack of diverse, effective, and affordable vaccine candidates in the global pipeline.
A GMP platform for live attenuated vaccines and a set of biomarkers for lung immune protection. It also includes new delivery systems and adjuvanted formulations.
If you are a vaccine developer dealing with the failure of BCG to prevent adult pulmonary TB — this project developed a GMP platform for live attenuated vaccines that accelerates the creation of more effective candidates.
If you are a biotech firm dealing with inefficient vaccine delivery to the lungs — this project developed novel delivery systems and adjuvanted formulations that target mucosal immunity.
If you are a diagnostics company dealing with a lack of ways to measure vaccine success — this project developed host immune response profiles and biomarkers of protection in the lung.
Based on available project data, specific pricing is not mentioned, but the objective is to ensure the developed vaccines are affordable and accessible.
The project is developing a new GMP (Good Manufacturing Practice) platform for live attenuated vaccines, which is a critical step toward industrial scaling.
Based on available project data, specific licensing terms are not provided, but a dedicated workpackage (WP5) manages the exploitation of results.
The project runs from 2023-04-01 to 2027-03-31, focusing on translating research toward clinical evaluation.
The project aims to fill the global vaccine pipeline with candidates that can be implemented to meet WHO End TB strategy goals.
The consortium is heavily weighted toward research and academia, featuring 8 universities and 7 research institutions. With only 1 industry partner (a 5% ratio), the project is primarily driven by scientific discovery and validation. However, the coordination by TBVI and the inclusion of 19 partners across 8 countries suggests a strong international network for scaling results.
Contact Stichting Tuberculosis Vaccine Initiative (TBVI) in the Netherlands.
Contact us to identify licensing opportunities for the new GMP vaccine platform.
